Related Experiment Video
Updated: Dec 8, 2025

Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface
Published on: August 11, 2017
A validated UPLC method for the determination of process-related impurities in bulk drug
Prakash M Davadra1, Vivek V Mepal1, Mukul R Jain1
1Zydus Research Centre, Sarkhej-Bavla N. H. No. 8A, Moraiya, Ahmedabad, 382 210, Gujarat, India. prakashdavadra@zyduscadila.
Abstract:
An UPLC method has been developed and subsequently validated for the determination of Azathioprine and its process-related impurities. Separation was achieved with Acquity UPLC BEH C18, 100 × 2.1 mm, 1.7 μm column and trifluoroacetic acid (0.05% in water) : acetonitrile as eluent in gradient mode. Flow rate was set at 0.35 mL min-1. UV detection was performed at 220 nm. The method has been validated with respect to specificity, accuracy, precision, linearity, robustness, limit of quantification and limit of detection. The accuracy of the method demonstrated at three levels in the range of 50-150% of the specification limit and the recovery of impurities were found to be in the range of 98 to 102%. The detection limits of the process related impurities ranged between 0.16 and 0.24 μg mL-1. The described method is simple, rapid, linear, precise and robust. The method is useful during process development and quality control of bulk manufacturing.
More Related Videos
10:22Improved UPLC-UV Method for the Quantification of Vitamin C in Lettuce Varieties Lactuca sativa L. and Crop Wild Relatives Lactuca spp.
Published on: June 30, 2020
11:00Untargeted Metabolomics from Biological Sources Using Ultraperformance Liquid Chromatography-High Resolution Mass Spectrometry UPLC-HRMS
Published on: May 20, 2013
Related Concept Videos
In Vitro Drug Release Testing: Overview, Development and Validation
Data Validation
Key parameters for method validation include:
High-Performance Liquid Chromatography: Elution Process
In Vitro Drug Dissolution: Compendial Testing Models II
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Clinically Relevant Drug Product Specifications: Methods of Establishment